CrushSCI.com
262.7Average days
262Median days
180Fastest days
364Longest days
4512025 publications

Paper Review Records

All Paper Review Records

6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

180 days

CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance

Authors
Tiffany R. King-Peoples; John T. Keane; Hyeon-Gyu S. Lewis; Fang Liu; Shawna K. Brookens; Oula K. Dagher; Kalpana Parvathaneni; Brittany L. Gardner; Amal Ahmed; Emma E. Furth; Priti Lal; Avery D. PoseyShow moreShow less
Affiliations
1. University of Pennsylvania 1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 2. University of Pennsylvania 2 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 3. 3Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.Show moreShow less
Source PDF DOI Publisher page
231 days

In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models

Authors
Trishna Debnath; Won Jong Jin; Ravi B. Patel; Peter M. Carlson; Md Mahfuzur Rahman; Tracy J. Berg; Caroline P. Kerr; Rene Welch Schwartz; Yujuan Wang; Meredith Hyun; Irene M. Ong; Jamey P. Weichert; Reinier Hernandez; Paul M. Sondel; Zachary S. MorrisShow moreShow less
Affiliations
1. 1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 2. 2Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.; 3. Emory University 3 Department of Pediatrics, , Atlanta, Georgia.; 4. 4Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 5. 5Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 6. 6Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 7. 7Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.Show moreShow less
Source PDF DOI Publisher page
293 days

VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer

Authors
Chuying Huo; Xibo Zhao; Dongdong Ye; Shaodan Lin; Dongdong Xu; Suen Wai Pang; Miaochun Xu; Junting Chen; Chunxian Huang; Yunyun Liu; Aoshuang Cheng; Lingjie Yang; Zhongqiu Lin; Lijuan Wang; Bowen Li; Huaiwu LuShow moreShow less
Affiliations
1. Sun Yat-sen Memorial Hospital 1 Department of Gynecologic Oncology, , Sun Yat-sen University, Guangzhou, China.; 2. Sun Yat-sen Memorial Hospital 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, , Sun Yat-sen University, Guangzhou, China.; 3. Sun Yat-sen Memorial Hospital 3 Department of Radiology, , Sun Yat-sen University, Guangzhou, China.; 4. Sun Yat-sen Memorial Hospital 4 Department of Oral and Maxillofacial Surgery, , Sun Yat-sen University, Guangzhou, China.Show moreShow less
Source PDF DOI Publisher page
308 days

Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity

Authors
Daisuke Ehara; Kiyoshi Yasui; Mitsuhiro Yoneda; Daisuke Muraoka; Situo Deng; Pengyu Miao; Chenxu Jiang; Huimin Sun; Sachiko Okamoto; Yasunori Amaishi; Hiroyuki Murota; Hiroaki IkedaShow moreShow less
Affiliations
1. 1Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; 2. 2Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; 3. 3Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.; 4. 4Takara Bio Inc., Kusatsu, Japan.; 5. 5Leading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.Show moreShow less
Source PDF DOI Publisher page
364 days

Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity

Authors
Daniel R. Lu; Tao Osgood; Shining Ma; Huajia Zhang; Matt Kanke; Jessica A. Tan; Siddhi N. Paudel; Hong Zhou; Juan Estrada; Tracy Yamawaki; Kristin Tarbell; Karen Rex; Jason DeVoss; Scott Martin; Songli Wang; Jude Canon; J. Russell Lipford; Angela Coxon; Chi-Ming LiShow moreShow less
Affiliations
1. 1Target Discovery & Biology of DATA, Amgen Global Research, South San Francisco, California.; 2. 2Oncology Research, Amgen Global Research, Thousand Oaks, California.; 3. 3ARIA of DATA, Amgen Global Research, South San Francisco, California.; 4. Amgen Global Research 4 Oncology Research, , South San Francisco, California.Show moreShow less
Source PDF DOI Publisher page
200 days

Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy

Authors
Christianne Groeneveldt; Disha Vadgama; Anne Onrust-van Schoonhoven; Declan Whyte; Maaike M. Hofman; Nina E.M. Rozendaal; Menno van Nimwegen; Mike Eterman; Daphne W. Dumoulin; Ron H.J. Mathijssen; Arjen Joosse; Astrid A.M. van der Veldt; Louis Boon; Michail Doukas; Janneke N. Samsom; Ralph Stadhouders; Floris Dammeijer; Joachim G.J.V. Aerts; Maria E. JoosseShow moreShow less
Affiliations
1. Department of Pulmonary Medicine, Erasmus University Medical Center , Rotterdam, the Netherlands.; 2. Erasmus MC Cancer Institute , Erasmus University Medical Center, Rotterdam, the Netherlands.; 3. Department of Medical Oncology, Erasmus University Medical Center , Rotterdam, the Netherlands.; 4. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center , Rotterdam, the Netherlands.; 5. JJP Biologics, Warsaw, Poland.; 6. Department of Pathology, Erasmus University Medical Center , Rotterdam, the Netherlands.; 7. Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center-Sophia Children’s Hospital, Rotterdam, the Netherlands.Show moreShow less
Source PDF DOI Publisher page

FAQ

How long does Cancer Immunology Research take to review a manuscript?

As of 2026-11-19, CrushSCI has 6 complete review records for Cancer Immunology Research. The fastest paper went from submission to acceptance in 180 days (CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance, received 2026-01-02, accepted 2026-07-01); the slowest took 364 days. The average is 262.7 days and the median is 262 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.